Papers
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
BMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7274.1440 (Published 09 December 2000) Cite this as: BMJ 2000;321:1440Related articles
- This Week In The BMJ Published: 09 December 2000; BMJ 321 doi:10.1136/bmj.321.7274.0/c
- Research Published: 28 January 2013; BMJ 346 doi:10.1136/bmj.f360
See more
- Sixty seconds on . . . 10 000 stepsBMJ March 08, 2024, 384 q598; DOI: https://doi.org/10.1136/bmj.q598
- Scarlett McNally: Enabling active travel can improve the UK’s healthBMJ March 06, 2024, 384 q522; DOI: https://doi.org/10.1136/bmj.q522
- Scarlett McNally: Boosting swimming for health and joyBMJ February 20, 2024, 384 q393; DOI: https://doi.org/10.1136/bmj.q393
- Variability in blood pressure could help predict heart attack and stroke risk, researchers sayBMJ February 09, 2024, 384 q363; DOI: https://doi.org/10.1136/bmj.q363
- Scarlett McNally: Preventing obesity is different from curing it—and even more urgentBMJ January 23, 2024, 384 q134; DOI: https://doi.org/10.1136/bmj.q134
Cited by...
- Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade
- Use of Renin-Angiotensin Inhibitors in People with Renal Artery Stenosis
- Standards of Medical Care in Diabetes--2014
- Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials
- Standards of Medical Care in Diabetes--2013
- The Effect of Direct Renin Inhibition Alone and in Combination With ACE Inhibition on Endothelial Function, Arterial Stiffness, and Renal Function in Type 1 Diabetes
- Standards of Medical Care in Diabetes--2012
- Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension
- Standards of Medical Care in Diabetes--2011
- Proteinuria in Diabetes: Bystander or Pathway to Cardiorenal Disease?
- Microvascular complications: pathophysiology and management
- Chronic Kidney Disease in Primary Care
- Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
- Standards of Medical Care in Diabetes--2010
- Standards of Medical Care in Diabetes--2009
- Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes
- Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease
- Intracardiac and Intrarenal Renin-Angiotensin Systems: Mechanisms of Cardiovascular and Renal Effects
- Renin: friend or foe?
- Treating Diabetic Nephropathy: Unfinished Success Is Not Failure
- Dual Blockade of the Renin-Angiotensin System in the Progression of Renal Disease: The Need for More Clinical Trials
- Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors
- Managing hypertension in patients with type 2 diabetes mellitus.
- Preventing Renal Complications in Type 2 Diabetes: Results of the Diabetics Exposed to Telmisartan and Enalapril Trial
- Economic Evaluation of Angiotensin Receptor Blockers in Type 2 Diabetes, Hypertension, and Nephropathy
- Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy
- Advanced Glycation End Products Activate a Chymase-Dependent Angiotensin II-Generating Pathway in Diabetic Complications
- Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy.
- Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes
- Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study
- Hypertension in type 2 diabetes - targeting angiotensin
- Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and an Angiotensin II Receptor Blocker Synergistically Suppresses Chronic Pancreatitis in Rats
- Renin Inhibition: What Are the Therapeutic Opportunities?
- Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal Disease
- Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes: The CALM II study
- Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents
- Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
- Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso
- Recent advances in diabetic nephropathy
- Diabetes Complications
- Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists
- ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection?
- Cardiovascular and Renal Risk Assessment as a Guide for Treatment in Primary Hypertension
- Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist
- Management of Glomerular Proteinuria: A Commentary
- Renoprotective efficacy of renin-angiotensin inhibitors in IgA nephropathy is influenced by ACE A2350G polymorphism
- Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy: A randomized double-blind crossover trial
- Prevention of the Development and Progression of Renal Disease
- Chymase Is Upregulated in Diabetic Nephropathy: Implications for an Alternative Pathway of Angiotensin II-Mediated Diabetic Renal and Vascular Disease
- Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIER
- Epidemic of Diabetic and Nondiabetic Renal Disease among the Zuni Indians: The Zuni Kidney Project
- Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy
- N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Inhibits TGF-{beta}-Mediated Plasminogen Activator Inhibitor-1 Expression via Inhibition of Smad Pathway in Human Mesangial Cells
- Diabetic Kidney Disease: Preventing Dialysis and Transplantation
- Enalapril and Losartan Reduce Sympathetic Hyperactivity in Patients with Chronic Renal Failure
- Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor?
- Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy: A double-blind randomized cross-over study
- The Next Treatments of Chronic Kidney Disease: If We Find Them, Can We Test Them?
- How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach
- Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
- Irbesartan Reduces the Albumin Excretion Rate in Microalbuminuric Type 2 Diabetic Patients Independently of Hypertension: A randomized double-blind placebo-controlled crossover study
- Diabetic Nephropathy: Can Renoprotection Be Extrapolated to Cardiovascular Protection?
- Diabetic nephropathy
- Chronic renal disease
- ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease
- Effects of Low-Dose and Early versus Late Perindopril Treatment on the Progression of Severe Diabetic Nephropathy in (mREN-2)27 Rats
- Induction of Functional Bradykinin B1-Receptors in Normotensive Rats and Mice Under Chronic Angiotensin-Converting Enzyme Inhibitor Treatment
- The Treatment of Hypertension in Adult Patients With Diabetes
- Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy: A randomized double-blind crossover study
- Diabetes and Hypertension
- Combination therapy with candesartan and lisinopril was more effective than monotherapy in type 2 diabetes and hypertension
- Dual blockade of renin-angiotensin system
- Dual Blockade of the Renin-Angiotensin System in Diabetes
- Dual Blockade of the Renin-Angiotensin System in Diabetes